Risk and Management of Intracerebral Hemorrhage in Patients with Bleeding Disorders

Abstract

Intracerebral hemorrhage (ICH) is the most dreaded complication, and the main cause of death, in patients with congenital bleeding disorders. ICH can occur in all congenital bleeding disorders, ranging from mild, like some platelet function disorders, to severe disorders such as hemophilia A, which can cause catastrophic hemorrhage. While extremely rare in mild bleeding disorders, ICH is common in severe coagulation factor (F) XIII deficiency. ICH can be spontaneous or trauma-related. Spontaneous ICH occurs more often in adults, while trauma-related ICH is more prevalent in children. Risk factors that can affect the occurrence of ICH include the type of bleeding disorder and its severity, genotype and genetic polymorphisms, type of delivery, and sports and other activities. Patients with hemophilia A; afibrinogenemia; FXIII, FX, and FVII deficiencies; and type 3 von Willebrand disease are more susceptible than those with mild platelet function disorders, FV, FXI, combined FV–FVIII deficiencies, and type 1 von Willebrand disease. Generally, the more severe the disorder, the more likely the occurrence of ICH. Contact sports and activities can provoke ICH, while safe and noncontact sports present more benefit than danger. An important risk factor is stressful delivery, whether it is prolonged or by vacuum extraction. These should be avoided in patients with congenital bleeding disorders. Familiarity with all risk factors of ICH can help prevent occurrence of this diathesis and reduce related morbidity and mortality.

Keywords

intracerebral hemorrhage - congenital bleeding disorders - morbidity - mortality

Publikationsverlauf

Artikel online veröffentlicht:
06. Januar 2022

• References

• 1 Dorgalaleh A, Rad F. Congenital bleeding disorders. In: Dorgalaleh A. eds. Congenital Bleeding Disorders. Springer, Cham; 2018: 27-53
• 2 Dorgalaleh A, Tabibian S, Hosseini MS, Shams M. Pharmacological management of rare coagulation factor deficiencies besides hemophilia. Expert Rev Hematol 2020; 13 (08) 811-834
• 3 Srivastava A, Brewer AK, Mauser-Bunschoten EP. et al; Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013; 19 (01) e1-e47
• 4 Tabibian S, Motlagh H, Naderi M, Dorgalaleh A. Intracranial hemorrhage in congenital bleeding disorders. Blood Coagul Fibrinolysis 2018; 29 (01) 1-11
• 5 Alavi SER, Jalalvand M, Assadollahi V, Tabibian S, Dorgalaleh A. Intracranial hemorrhage: a devastating outcome of congenital bleeding disorders—prevalence, diagnosis, and management, with a special focus on congenital factor XIII deficiency. Semin Thromb Hemost 2018; 44 (03) 267-275
• 6 Kidwell CS, Wintermark M. Imaging of intracranial haemorrhage. Lancet Neurol 2008; 7 (03) 256-267
• 7 Macellari F, Paciaroni M, Agnelli G, Caso V. Neuroimaging in intracerebral hemorrhage. Stroke 2014; 45 (03) 903-908
• 8 Dorgalaleh A, Naderi M, Shamsizadeh M. Morbidity and mortality in a large number of Iranian patients with severe congenital factor XIII deficiency. Ann Hematol 2016; 95 (03) 451-455
• 9 Nagel K, Pai MK, Paes BA, Chan AK. Diagnosis and treatment of intracranial hemorrhage in children with hemophilia. Blood Coagul Fibrinolysis 2013; 24 (01) 23-27
• 10 Ljung RC. Intracranial haemorrhage in haemophilia A and B. Br J Haematol 2008; 140 (04) 378-384
• 11 Lak M, Keihani M, Elahi F, Peyvandi F, Mannucci PM. Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia. Br J Haematol 1999; 107 (01) 204-206
• 12 Lak M, Sharifian R, Peyvandi F, Mannucci PM. Symptoms of inherited factor V deficiency in 35 Iranian patients. Br J Haematol 1998; 103 (04) 1067-1069
• 13 Mariani G, Herrmann FH, Dolce A. et al; International Factor VII Deficiency Study Group. Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. Thromb Haemost 2005; 93 (03) 481-487
• 14 Peyvandi F, Mannucci PM, Lak M. et al. Congenital factor X deficiency: spectrum of bleeding symptoms in 32 Iranian patients. Br J Haematol 1998; 102 (02) 626-628
• 15 Federici AB, Bucciarelli P, Castaman G. et al. Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients. Semin Thromb Hemost 2011; 37 (05) 511-521
• 16 Zanon E, Pasca S. Intracranial haemorrhage in children and adults with haemophilia A and B: a literature review of the last 20 years. Blood Transfus 2019; 17 (05) 378-384
• 17 Mauser Bunschoten EP, van Houwelingen JC, Sjamsoedin Visser EJ, van Dijken PJ, Kok AJ, Sixma JJ. Bleeding symptoms in carriers of hemophilia A and B. Thromb Haemost 1988; 59 (03) 349-352
• 18 Brown D. Hemophilia A and B: diagnosis and management. In: Nonmalignant Hematology. Springer; 2016: 255-262
• 19 Witmer C, Presley R, Kulkarni R, Soucie JM, Manno CS, Raffini L. Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States. Br J Haematol 2011; 152 (02) 211-216
• 20 Kulkarni R, Soucie JM, Lusher J. et al; Haemophilia Treatment Center Network Investigators. Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from The Centers for Disease Control and Prevention's (CDC) Universal Data Collection (UDC) project. Haemophilia 2009; 15 (06) 1281-1290
• 21 Myles LM, Massicotte P, Drake J. Intracranial hemorrhage in neonates with unrecognized hemophilia A: a persisting problem. Pediatr Neurosurg 2001; 34 (02) 94-97
• 22 Cho JY, Lee WS, Park YS, Lee SH, Koh JS. Clinical characteristics and prognostic factors in hemophiliacs with intracranial hemorrhage: a single-center, retrospective experience. Indian J Hematol Blood Transfus 2016; 32 (04) 488-493
• 23 Hu Q, Zhang A, Liu AG, Wang SM, Wang YQ, Zhang LQ. A retrospective analysis of intracranial hemorrhage in children with hemophilia A. Curr Med Sci 2018; 38 (05) 875-879
• 24 Richards M, Lavigne Lissalde G, Combescure C. et al; European Haemophilia Treatment and Standardization Board. Neonatal bleeding in haemophilia: a European cohort study. Br J Haematol 2012; 156 (03) 374-382
• 25 Bladen M, Main E, Khair K, Hubert N, Koutoumanou E, Liesner R. The incidence, risk and functional outcomes of intracranial haemorrhage in children with inherited bleeding disorders at one haemophilia center. Haemophilia 2016; 22 (04) 556-563
• 26 Andersson NG, Auerswald G, Barnes C. et al. Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment. Br J Haematol 2017; 179 (02) 298-307
• 27 Mishra P, Naithani R, Dolai T. et al. Intracranial haemorrhage in patients with congenital haemostatic defects. Haemophilia 2008; 14 (05) 952-955
• 28 de Tezanos Pinto M, Fernandez J, Perez Bianco PR. Update of 156 episodes of central nervous system bleeding in hemophiliacs. Haemostasis 1992; 22 (05) 259-267
• 29 Ghosh K, Nair AP, Jijina F, Madkaikar M, Shetty S, Mohanty D. Intracranial haemorrhage in severe haemophilia: prevalence and outcome in a developing country. Haemophilia 2005; 11 (05) 459-462
• 30 Nuss R, Soucie JM, Evatt B. Hemophilia Surveillance System Project Investigators. Changes in the occurrence of and risk factors for hemophilia-associated intracranial hemorrhage. Am J Hematol 2001; 68 (01) 37-42
• 31 Tosetto A, Badiee Z, Baghaipour MR. et al. Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: results from 3WINTERS-IPS, an international and collaborative cross-sectional study. J Thromb Haemost 2020; 18 (09) 2145-2154
• 32 Sadler JE, Mannucci PM, Berntorp E. et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000; 84 (02) 160-174
• 33 Labarque V, Stain AM, Blanchette V, Kahr WH, Carcao MD. Intracranial haemorrhage in von Willebrand disease: a report on six cases. Haemophilia 2013; 19 (04) 602-606
• 34 Wetzstein V, Budde U, Oyen F. et al. Intracranial hemorrhage in a term newborn with severe von Willebrand disease type 3 associated with sinus venous thrombosis. Haematologica 2006; 91 (12, Suppl): ECR60-ECR
• 35 Peyvandi F, Jayandharan G, Chandy M. et al. Genetic diagnosis of haemophilia and other inherited bleeding disorders. Haemophilia 2006; 12 (Suppl. 03) 82-89
• 36 Peyvandi F, Menegatti M, Palla R. Rare bleeding disorders: worldwide efforts for classification, diagnosis, and management. Semin Thromb Hemost 2013; 39 (06) 579-584
• 37 Borhany M, Pahore Z, Ul Qadr Z. et al. Bleeding disorders in the tribe: result of consanguineous in breeding. Orphanet J Rare Dis 2010; 5 (01) 23
• 38 Palla R, Peyvandi F, Shapiro ADJB. The Journal of the American Society of Hematology. Rare bleeding disorders: diagnosis and treatment. Blood 2015; 125 (13) 2052-2061
• 39 Jain S, Acharya SSJT. Management of rare coagulation disorders in 2018. Transfus Apheresis Sci 2018; 57 (06) 705-712
• 40 Shams M, Dorgalaleh A, Safarian N. et al. Inhibitor development in patients with congenital factor VII deficiency, a study on 50 Iranian patients. Blood Coagul Fibrinolysis 2019; 30 (01) 24-28
• 41 W Collins P, Chalmers E, Hart D. et al; United Kingdom Haemophilia Centre Doctors' Organization. Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO. Br J Haematol 2013; 162 (06) 758-773
• 42 Ramezanpour N, Zaker F, Biswas A, Dorgalaleh A. Inhibitor in congenital factor VII deficiency; a rare but serious therapeutic challenge-a systematic literature review. J Clin Med 2021; 10 (02) 211
• 43 Dorgalaleh A, Motlagh H, Tabibian SH, Naderi M. Burden of congenital factor XIII deficiency in Iran. J Cell Mol Anesth. 2017; 2 (03) 142-145
• 44 Peyvandi F, Palla R, Menegatti M, Mannucci PM. Introduction. Rare bleeding disorders: general aspects of clinical features, diagnosis, and management. Semin Thromb Hemost 2009; 35 (04) 349-355
• 45 Robinson KS. An overview of inherited factor VII deficiency. Transfus Apheresis Sci 2019; 58 (05) 569-571
• 46 Takamiya O, Okimoto Y. Severe factor VII deficiency with recurrent intracranial haemorrhages owing to double heterozygosity for a splice site mutation of an IVS4 and a novel nonsense mutation in exon 8 (Gln211–>Term). Br J Haematol 2001; 114 (02) 369-374
• 47 Brown DL, Kouides PA. Diagnosis and treatment of inherited factor X deficiency. Haemophilia 2008; 14 (06) 1176-1182
• 48 Tan AP, Svrckova P, Cowan F, Chong WK, Mankad K. Intracranial hemorrhage in neonates: a review of etiologies, patterns and predicted clinical outcomes. Eur J Paediatr Neurol 2018; 22 (04) 690-717
• 49 Cattaneo M. Inherited platelet-based bleeding disorders. J Thromb Haemost 2003; 1 (07) 1628-1636
• 50 Lee A, Poon MC. Inherited platelet functional disorders: general principles and practical aspects of management. Transfus Apheresis Sci 2018; 57 (04) 494-501
• 51 Franchini M, Favaloro EJ, Lippi G. Glanzmann thrombasthenia: an update. Clin Chim Acta 2010; 411 (1-2): 1-6
• 52 Nurden AT, Nurden P. The gray platelet syndrome: clinical spectrum of the disease. Blood Rev 2007; 21 (01) 21-36
• 53 Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS, Jordan RE. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 1996; 88 (03) 907-914
• 54 George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood 1990; 75 (07) 1383-1395
• 55 Rosas RR, Kurth MH, Sidman J. Treatment and outcomes for epistaxis in children with Glanzmann's thrombasthenia. Laryngoscope 2010; 120 (12) 2374-2377
• 56 Afrasiabi A, Artoni A, Karimi M, Peyvandi F, Ashouri E, Mannucci PM. Glanzmann thrombasthenia and Bernard-Soulier syndrome in south Iran. Clin Lab Haematol 2005; 27 (05) 324-327
• 57 Zanon E, Iorio A, Rocino A. et al; Italian Association of Hemophilia Centers. Intracranial haemorrhage in the Italian population of haemophilia patients with and without inhibitors. Haemophilia 2012; 18 (01) 39-45
• 58 Arkin S, Cooper HA, Hutter JJ. et al. Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors. Results of the novoseven emergency-use program. Haemostasis 1998; 28 (02) 93-98
• 59 Franchini M, Girelli D, Olivieri O. et al. Tyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A. Haemophilia 2006; 12 (04) 448-451
• 60 Kulkarni R, Lusher J. Perinatal management of newborns with haemophilia. Br J Haematol 2001; 112 (02) 264-274
• 61 Andreasen TH, Bartek Jr J, Andresen M, Springborg JB, Romner B. Modifiable risk factors for aneurysmal subarachnoid hemorrhage. Stroke 2013; 44 (12) 3607-3612
• 62 Johansson K, Jansson J-H, Johansson L, Ekblom K, Lind MM. Von Willebrand factor, ABO blood group, and risk of first-ever intracerebral hemorrhage: a prospective nested case-control study. Thromb Res 2020; 195: 77-80
• 63 Albánez S, Ogiwara K, Michels A. et al. Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms. J Thromb Haemost 2016; 14 (05) 953-963
• 64 Johansson L, Jansson JH, Stegmayr B, Nilsson TK, Hallmans G, Boman K. Hemostatic factors as risk markers for intracerebral hemorrhage: a prospective incident case-referent study. Stroke 2004; 35 (04) 826-830
• 65 Meeks SL, Abshire TC. Abnormalities of prothrombin: a review of the pathophysiology, diagnosis, and treatment. Haemophilia 2008; 14 (06) 1159-1163
• 66 Lancellotti S, Basso M, De Cristofaro R. Congenital prothrombin deficiency: an update. Semin Thromb Hemost 2013; 39 (06) 596-606
• 67 Dorgalaleh A, Alavi SER, Tabibian S. et al. Diagnosis, clinical manifestations and management of rare bleeding disorders in Iran. Hematology 2017; 22 (04) 224-230
• 68 Oldenburg J, von Brederlow B, Fregin A. et al. Congenital deficiency of vitamin K dependent coagulation factors in two families presents as a genetic defect of the vitamin K-epoxide-reductase-complex. Thromb Haemost 2000; 84 (06) 937-941
• 69 Rost S, Fregin A, Ivaskevicius V. et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427 (6974): 537-541
• 70 Traivaree C, Monsereenusorn C, Meekaewkunchorn A, Laoyookhong P, Suwansingh S, Boonyawat B. Genotype and phenotype correlation in intracranial hemorrhage in neonatal factor VII deficiency among Thai children. Appl Clin Genet 2017; 10: 37-41
• 71 Herrmann FH, Auerswald G, Ruiz-Saez A. et al; Greifswald Factor X Deficiency Study Group. Factor X deficiency: clinical manifestation of 102 subjects from Europe and Latin America with mutations in the factor 10 gene. Haemophilia 2006; 12 (05) 479-489
• 72 Daneshi M, Naderi T, Tabibian S, Shams M, Rashidpanah J. Dorgalaleh. Congenital prothrombin deficiency. J Cell Mol Anesth. 2018; 3 (04) 146-154
• 73 Carpenter AM, Singh IP, Gandhi CD, Prestigiacomo CJ. Genetic risk factors for spontaneous intracerebral haemorrhage. Nat Rev Neurol 2016; 12 (01) 40-49
• 74 Siboni SM, Zanon E, Sottilotta G. et al. Central nervous system bleeding in patients with rare bleeding disorders. Haemophilia 2012; 18 (01) 34-38
• 75 Moorehead PC, Chan AKC, Lemyre B. et al. A practical guide to the management of the fetus and newborn with hemophilia. Clin Appl Thromb Hemost 2018; 24 (9 Suppl): 29S-41S
• 76 Davies J, Kadir RA. Mode of delivery and cranial bleeding in newborns with haemophilia: a systematic review and meta-analysis of the literature. Haemophilia 2016; 22 (01) 32-38
• 77 Huq FY, Kadir RA. Management of pregnancy, labour and delivery in women with inherited bleeding disorders. Haemophilia 2011; 17 (Suppl. 01) 20-30
• 78 Napolitano M, Giansily-Blaizot M, Dolce A. et al. Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER). Haematologica 2013; 98 (04) 538-544
• 79 Chalmers E, Williams M, Brennand J, Liesner R, Collins P, Richards M. Paediatric Working Party of United Kingdom Haemophilia Doctors' Organization. Guideline on the management of haemophilia in the fetus and neonate. Br J Haematol 2011; 154 (02) 208-215
• 80 Maffet M, Roton Jr J. Hemophilia in sports: a case report and prophylactic protocol. J Athl Train 2017; 52 (01) 65-70
• 81 Franchini M, Fasoli S, Gandini G, Giuffrida AC. Impact of exercise/sport on well-being in congenital bleeding disorders. Semin Thromb Hemost 2018; 44 (08) 796-801
• 82 Bertamino M, Riccardi F, Banov L, Svahn J, Molinari AC. Hemophilia care in the pediatric age. J Clin Med 2017; 6 (05) 54
• 83 Ar MC, Balkan C, Kavaklı K. Extended half-life coagulation factors: a new era in the management of hemophilia patients. Turk J Haematol 2019; 36 (03) 141-154
• 84 Berntorp E, Petrini P. Long-term prophylaxis in von Willebrand disease. Blood Coagul Fibrinolysis 2005; 16 (Suppl. 01) S23-S26
• 85 Livnat T, Barg AA, Levy-Mendelovich S, Kenet G. Rare bleeding disorders-old diseases in the era of novel options for therapy. Blood Cells Mol Dis 2017; 67: 63-68
• 86 Shapiro A. The use of prophylaxis in the treatment of rare bleeding disorders. Thromb Res 2020; 196: 590-602
• 87 Nugent D. Corifact™/Fibrogammin® P in the prophylactic treatment of hereditary factor XIII deficiency: results of a prospective, multicenter, open-label study. Thromb Res 2012; 130 (Suppl. 02) S12-S14
• 88 Naderi M, Dorgalaleh A, Alizadeh S. et al. Clinical manifestations and management of life-threatening bleeding in the largest group of patients with severe factor XIII deficiency. Int J Hematol 2014; 100 (05) 443-449
• 89 DesPain AW, Kshetrapal A, Kousa YA. et al. Management of intracranial hemorrhage in severe factor V deficiency and definitive treatment with liver transplantation. Pediatr Transplant 2018; 22 (01) e13102
• 90 Peyvandi F, Menegatti M. Treatment of rare factor deficiencies in 2016. Hematology (Am Soc Hematol Educ Program) 2016; 2016 (01) 663-669
• 91 Hünseler C, Kribs A, Eifinger F, Roth B. Recombinant activated factor seven in acute life-threatening bleeding in neonates: report on three cases and review of literature. J Perinatol 2006; 26 (11) 706-713
• 92 Mayer SA, Brun NC, Begtrup K. et al; Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352 (08) 777-785
• 93 Knight RD, Barr CF, Alving BM. Replacement therapy for congenital Factor X deficiency. Transfusion 1985; 25 (01) 78-80
• 94 Solh T, Botsford A, Solh M. Glanzmann's thrombasthenia: pathogenesis, diagnosis, and current and emerging treatment options. J Blood Med 2015; 6: 219-227
• 95 Kirchmaier CM, Pillitteri D. Diagnosis and management of inherited platelet disorders. Transfus Med Hemother 2010; 37 (05) 237-246
• 96 Eshuis-Peters E, Versluys AB, Stokman MF, van der Crabben SN, Nij Bijvank SW, van Wezel-Meijler G. Congenital amegakaryocytic thrombocytopenia type II presenting with multiple central nervous system anomalies. Neuropediatrics 2016; 47 (02) 128-131
• 97 Broderick J, Connolly S, Feldmann E. et al; American Heart Association, American Stroke Association Stroke Council, High Blood Pressure Research Council, Quality of Care and Outcomes in Research Interdisciplinary Working Group. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke 2007; 38 (06) 2001-2023
• 98 Zanon E, Pasca S, Bertomoro A, Mardari R, Simioni P. Spontaneous recurrent intracranial haemorrhage in a woman with type 2B von Willebrand disease: a clinical case and a brief literature review. Haemophilia 2019; 25 (04) e282-e285
• 99 Tatlı Güneş B, Önder Siviş Z, Ataseven E. et al. Intracranial bleeding in a female hemophilia patient: molecular analysis of the Factor 8 gene and determination of a novel mutation. Turk J Haematol 2018; 35 (03) 202-203
• 100 Neerman-Arbez M, de Moerloose P. Mutations in the fibrinogen gene cluster accounting for congenital afibrinogenemia: an update and report of 10 novel mutations. Hum Mutat 2007; 28 (06) 540-553
• 101 Asselta R, Robusto M, Platé M, Santoro C, Peyvandi F, Duga S. Molecular characterization of 7 patients affected by dys- or hypo-dysfibrinogenemia: identification of a novel mutation in the fibrinogen Bbeta chain causing a gain of glycosylation. Thromb Res 2015; 136 (01) 168-174
• 102 Nuzzo F, Beshlawi I, Wali Y, Castoldi E. High incidence of intracranial bleeding in factor V-deficient patients with homozygous F5 splicing mutations. Br J Haematol 2017; 179 (01) 163-166
• 103 Landau D, Rosenberg N, Zivelin A, Staretz-Chacham O, Kapelushnik J. Familial factor VII deficiency with foetal and neonatal fatal cerebral haemorrhage associated with homozygosis to Gly180Arg mutation. Haemophilia 2009; 15 (03) 774-778
• 104 Lee JH, Lee HJ, Bin JH. et al. A novel homozygous missense mutation in the factor VII gene of severe factor VII deficiency in a newborn baby. Blood Coagul Fibrinolysis 2009; 20 (02) 161-164
• 105 Herrmann FH, Wulff K, Auerswald G. et al; Greifswald Factor FVII Deficiency Study Group. Factor VII deficiency: clinical manifestation of 717 subjects from Europe and Latin America with mutations in the factor 7 gene. Haemophilia 2009; 15 (01) 267-280
• 106 Giansily-Blaizot M, Aguilar-Martinez P, Briquel M-E. et al. Two novel cases of cerebral haemorrhages at the neonatal period associated with inherited factor VII deficiency, one of them revealing a new nonsense mutation (Ser52Stop). Blood Coagul Fibrinolysis 2003; 14 (02) 217-220
• 107 He J, Zhou W, Lv H, Tao L, Chen X, Wang L. Novel IVS7+1G>T mutation of life-threatening congenital factor VII deficiency in neonates: a retrospective study in China. Medicine (Baltimore) 2019; 98 (40) e17360
• 108 Herrmann FH, Navarette M, Salazar-Sanchez L, Carillo JM, Auerswald G, Wulff K. Homozygous Factor X gene mutations Gly380Arg and Tyr163delAT are associated with perinatal intracranial hemorrhage. J Pediatr 2005; 146 (01) 128-130
• 109 Madhusoodhan PP, Lu BY, Chen J. et al. Splice site mutation in factor X gene manifesting as severe intracranial haemorrhage in neonatal period with a challenging treatment course. Haemophilia 2017; 23 (02) e138-e140
• 110 Rauch R, Girisch M, Wiegand G. et al. Factor X deficiency and intracranial bleeding: who is at risk?. Haemophilia 2011; 17 (05) 759-763
• 111 Akhavan S, Chafa O, Obame FN. et al. Recurrence of a Phe31Ser mutation in the Gla domain of blood coagulation factor X, in unrelated Algerian families: a founder effect?. Eur J Haematol 2007; 78 (05) 405-409
• 112 Karimi M, Menegatti M, Afrasiabi A, Sarikhani S, Peyvandi F. Phenotype and genotype report on homozygous and heterozygous patients with congenital factor X deficiency. Haematologica 2008; 93 (06) 934-938
• 113 Peyvandi F, Menegatti M, Santagostino E. et al. Gene mutations and three-dimensional structural analysis in 13 families with severe factor X deficiency. Br J Haematol 2002; 117 (03) 685-692
• 114 Mota L, Shetty S, Idicula-Thomas S, Ghosh K. Molecular basis of factor X deficiency cases from India. Haemophilia 2010; 16 (04) 693-697
• 115 Naderi M, Alizadeh S, Kazemi A. et al. Central nervous system bleeding in pediatric patients with factor XIII deficiency: a study on 23 new cases. Hematology 2015; 20 (02) 112-118
• 116 Peyvandi F, Tagliabue L, Menegatti M. et al. Phenotype-genotype characterization of 10 families with severe a subunit factor XIII deficiency. Hum Mutat 2004; 23 (01) 98
• 117 Dorgalaleh A, Assadollahi V, Tabibian S, Shamsizadeh M. Molecular basis of congenital factor XIII deficiency in Iran. Clin Appl Thromb Hemost 2018; 24 (02) 210-216
• 118 Louhichi N, Medhaffar M, Hadjsalem I. et al. Congenital factor XIII deficiency caused by two mutations in eight Tunisian families: molecular confirmation of a founder effect. Ann Hematol 2010; 89 (05) 499-504
• 119 Farah RA, Al Danaf JZ, Chahinian RA. et al. Spontaneous epidural hematoma in a child with inherited factor XIII deficiency. J Pediatr Hematol Oncol 2014; 36 (01) 62-65
• 120 Ivaskevicius V, Seitz R, Kohler HP. et al; Study Group. International registry on factor XIII deficiency: a basis formed mostly on European data. Thromb Haemost 2007; 97 (06) 914-921
• 121 Wihadmadyatami H, Röder L, Berghöfer H. et al. Immunisation against αIIbβ3 and αvβ3 in a type 1 variant of Glanzmann's thrombasthenia caused by a missense mutation Gly540Asp on β3. Thromb Haemost 2016; 116 (02) 262-271